NZ531461A - Expandable gastric retention device - Google Patents

Expandable gastric retention device

Info

Publication number
NZ531461A
NZ531461A NZ531461A NZ53146101A NZ531461A NZ 531461 A NZ531461 A NZ 531461A NZ 531461 A NZ531461 A NZ 531461A NZ 53146101 A NZ53146101 A NZ 53146101A NZ 531461 A NZ531461 A NZ 531461A
Authority
NZ
New Zealand
Prior art keywords
agents
gastric retention
retention device
gel
gastric
Prior art date
Application number
NZ531461A
Other languages
English (en)
Inventor
James W Ayres
Original Assignee
Oregon State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oregon State filed Critical Oregon State
Publication of NZ531461A publication Critical patent/NZ531461A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0409—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0409—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
    • A61K49/0414—Particles, beads, capsules or spheres
    • A61K49/0419—Microparticles, microbeads, microcapsules, microspheres, i.e. having a size or diameter higher or equal to 1 micrometer

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Jellies, Jams, And Syrups (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
NZ531461A 2001-08-16 2001-10-22 Expandable gastric retention device NZ531461A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31307801P 2001-08-16 2001-08-16
PCT/US2001/046146 WO2003015745A1 (fr) 2001-08-16 2001-10-22 Dispositif de retention gastrique expansible

Publications (1)

Publication Number Publication Date
NZ531461A true NZ531461A (en) 2008-03-28

Family

ID=23214285

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ531461A NZ531461A (en) 2001-08-16 2001-10-22 Expandable gastric retention device

Country Status (14)

Country Link
EP (1) EP1416914A1 (fr)
JP (1) JP2005501097A (fr)
KR (1) KR20040032918A (fr)
CN (1) CN1543337A (fr)
BR (1) BR0117123A (fr)
CA (1) CA2456976A1 (fr)
CO (1) CO5670360A2 (fr)
IL (1) IL160363A0 (fr)
MX (1) MXPA04001388A (fr)
NO (1) NO20040611L (fr)
NZ (1) NZ531461A (fr)
PL (1) PL368327A1 (fr)
WO (1) WO2003015745A1 (fr)
ZA (1) ZA200402066B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003045308A2 (fr) 2001-11-21 2003-06-05 E-Z-Em, Inc. Formulations a utiliser dans les procedures medicales et diagnostiques
CA2550983C (fr) * 2003-12-24 2013-09-17 Advancis Pharmaceutical Corporation Absorption amelioree de formes de dosage a liberation modifiee
US7785291B2 (en) 2005-03-01 2010-08-31 Tulip Medical Ltd. Bioerodible self-deployable intragastric implants
US7699863B2 (en) 2005-03-01 2010-04-20 Tulip Medical Ltd. Bioerodible self-deployable intragastric implants
KR20090053783A (ko) * 2006-07-19 2009-05-27 스미스클라인 비참 코포레이션 감마 섬광조영술 평가를 위한 제형의 방사선표지 방법
CN102552103B (zh) * 2010-12-20 2013-11-20 西安力邦医药科技有限责任公司 拉米夫定固体分散体、其制备方法、药物组合物和用途
US10507127B2 (en) 2012-06-07 2019-12-17 Epitomee Medical Ltd. Expandable device
EP3091962B1 (fr) 2013-12-05 2022-06-08 Epitomee Medical Ltd. Dispositifs et systèmes de rétention pour la libération in-situ d'agents pharmaceutiques actifs
EP3725357A1 (fr) 2014-06-11 2020-10-21 Massachusetts Institute Of Technology Structures de résidence et procédés associés
US20170266112A1 (en) 2014-06-11 2017-09-21 Massachusetts Institute Of Technology Residence structures and related methods
WO2016178971A1 (fr) 2015-05-01 2016-11-10 Massachusetts Institute Of Technology Dispositifs d'induction à mémoire de forme pouvant être déclenchés
AU2016342374B2 (en) 2015-10-23 2022-08-04 Lyndra Therapeutics, Inc. Gastric residence systems for sustained release of therapeutic agents and methods of use thereof
KR20180090881A (ko) 2015-12-08 2018-08-13 린드라 인코퍼레이티드 위 체류 시스템을 위한 기하 구성형태
AU2017268840B2 (en) 2016-05-27 2022-02-10 Lyndra Therapeutics, Inc. Materials architecture for gastric residence systems
AU2017336154B2 (en) 2016-09-30 2023-11-09 Lyndra Therapeutics, Inc. Gastric residence systems for sustained delivery of adamantane-class drugs
WO2018227147A1 (fr) 2017-06-09 2018-12-13 Lyndra, Inc. Systèmes gastriques à demeure avec films modulant le taux de libération
US11337919B2 (en) * 2017-12-18 2022-05-24 Tris Pharma, Inc. Modified release drug powder composition comprising gastro-retentive RAFT forming systems having trigger pulse drug release
TR201914116A2 (tr) * 2019-09-17 2021-04-21 Univ Yeditepe Doğal bi̇yomateryaller i̇le kri̇yojelleri̇n üreti̇m yöntemi̇ ve bu kri̇yojelleri̇n yumuşak doku i̇skelesi̇ veya i̇laç taşiyici si̇stem olarak kullanimi
WO2022195476A1 (fr) 2021-03-15 2022-09-22 Clexio Biosciences Ltd. Dispositifs de rétention gastrique pour l'évaluation d'états intragastriques

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4764380A (en) * 1982-03-22 1988-08-16 Alza Corporation Drug delivery system comprising a volume increasing matrix containing a plurality of tiny pills
US5232704A (en) * 1990-12-19 1993-08-03 G. D. Searle & Co. Sustained release, bilayer buoyant dosage form
DE4406424A1 (de) * 1994-02-28 1995-08-31 Bayer Ag Expandierbare Arzneiformen
ES2234139T3 (es) * 1997-08-11 2005-06-16 Alza Corporation Forma de dosificacion de un agente activo de liberacion prolongada adaptada para la retencion gastrica.
EA004443B1 (ru) * 1998-09-14 2004-04-29 Рэнбакси Лабораториз Лимитед Лекарственная форма для контролируемого высвобождения ципрофлоксацина для приема один раз в день
JP2000256216A (ja) * 1999-03-04 2000-09-19 Meiji Milk Prod Co Ltd ゲル組成物
HUP0301465A3 (en) * 2000-06-23 2006-07-28 Teva Pharma Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition

Also Published As

Publication number Publication date
JP2005501097A (ja) 2005-01-13
MXPA04001388A (es) 2004-05-27
CN1543337A (zh) 2004-11-03
IL160363A0 (en) 2004-07-25
BR0117123A (pt) 2004-09-28
WO2003015745A1 (fr) 2003-02-27
PL368327A1 (en) 2005-03-21
ZA200402066B (en) 2005-05-09
NO20040611L (no) 2004-04-16
CO5670360A2 (es) 2006-08-31
CA2456976A1 (fr) 2003-02-27
EP1416914A1 (fr) 2004-05-12
KR20040032918A (ko) 2004-04-17

Similar Documents

Publication Publication Date Title
US20040219186A1 (en) Expandable gastric retention device
JP3382950B2 (ja) 医薬品用の徐放性マトリックス
Gopalakrishnan et al. Floating drug delivery systems: A Review
NZ531461A (en) Expandable gastric retention device
EP1750717B1 (fr) Compositions pharmaceutiques a liberation controlee presentant une meilleure biodisponibilite
KR100618234B1 (ko) 다공성 입자를 포함하는 제형
US20030203878A1 (en) Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
JPH0830007B2 (ja) 徐放性カプセル
AU2001268719A1 (en) Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
JP2002524494A (ja) 一時的および空間的制御を供する経口で投与された制御薬剤送出系
Vasave A REVIEW ON: FLOATING DRUG DELIVERY SYSTEM
US20240299304A1 (en) A method for the production of gastroretentive compact matrices for the controlled release of active substances and compact matrices thus obtained
JP4224866B2 (ja) 溶解時間を制御した基剤
JP3122478B2 (ja) 下部消化管放出型経口製剤
AU2002225872A1 (en) Expandable gastric retention device
Katakam et al. Floating drug delivery systems: a review
JP6585053B2 (ja) 胃内滞留型経口医薬組成物
Singh et al. Gastroretentive Delivery
WO2000016784A1 (fr) Systeme d'administration orale de medicament permettant d'ameliorer la biodisponibilite de la glycyrrhetine activee
JPWO2019039420A1 (ja) 医薬組成物粒子とそれを含む口腔内崩壊製剤、医薬組成物粒子の製造方法
Jaiswal Vicky et al. FLOATING MICROSPHERE: AN APPROACH TO ORAL CONTROLLED DRUG DELIVERY VIA GASTRIC RETENTION.

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
PSEA Patent sealed